Succinic Acid

Succinic Acid

SCHEMBL2585049

Clc1ccc2c(c1NCc1ccc(CN3CCCCC3)cc1)CCNCC2.O=C(O)CCC(=O)O

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4

The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HTR2A known ✓ P28223 2/20 0.37
HTR2C known ✓ P28335 1/20 0.36
HRH3 Q9Y5N1 6/20 0.40
CXCR4 P61073 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
POLB P06746 2/20 0.38
ACHE P22303 1/20 0.38
CHRM1 P11229 1/20 0.37
MCHR1 Q99705 1/20 0.37
GAA P10253 1/20 0.37
ALDH1A1 P00352 2/20 0.37
KDM4E B2RXH2 1/20 0.37
HTR2B P41595 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Succinic Acid SCHEMBL2580417 1.00 HRH3 (0.40) HRH3CXCR4SMN1; SMN2POLBACHE
Succinic Acid SCHEMBL2585669 0.99 CXCR4 (0.39) HRH3CXCR4SMN1; SMN2POLBACHE
SCHEMBL12160325 0.92 POLB (0.44) HRH3CXCR4SMN1; SMN2POLBHTR2A
SCHEMBL2586497 0.92 POLB (0.44) HRH3CXCR4SMN1; SMN2POLBHTR2A
SCHEMBL12160322 0.91 CXCR4 (0.44) HRH3CXCR4SMN1; SMN2POLBHTR2A
Succinic Acid SCHEMBL2585138 0.90 ALDH1A1 (0.42) HRH3SMN1; SMN2POLBALDH1A1KDM4E
Succinic Acid SCHEMBL506528 0.88 ALDH1A1 (0.41) HRH3SMN1; SMN2POLBGAAALDH1A1
Succinic Acid SCHEMBL506304 0.87 FFAR1 (0.44) HTR2AGAAALDH1A1HTR2CHTR2B
Succinic Acid SCHEMBL506757 0.85 POLB (0.46) SMN1; SMN2POLBGAAALDH1A1
Succinic Acid SCHEMBL2578398 0.84 HTR2B (0.38) HTR2AKDM4EHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1924561-B1 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS LILLY CO ELI (US) 2012-11-14 EP claimed
US-8680091-B2 6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists ELI LILLY AND COMPANY (US) 2014-03-25 US disclosed
EP-1924561-B1 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS LILLY CO ELI (US) 2012-11-14 EP disclosed
US-20110269745-A1 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2011-11-03 US disclosed
US-20080269196-A1 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists ELI LILLY AND COMPANY 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269745-A1 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS HTR2C, HTR1A, HTR2A HTR2A 3/4885HTR2C 1/4885HRH3 394/4885
US-20080269196-A1 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists HTR2C, HTR1A, HTR2A HTR2A 3/4885HTR2C 1/4885HRH3 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.